We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+7.34%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$2.13B
(+17%)
Cap. Flow
+$1.52B
Cap. Flow
% of AUM
10.28%
Top 10 Holdings %
Top 10 Hldgs %
17.14%
Holding
1,089
New
119
Increased
321
Reduced
473
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$132M |
| 2 |
Apple
AAPL
|
+$117M |
| 3 |
Microsoft
MSFT
|
+$100M |
| 4 |
Fidelity National Information Services
FIS
|
+$94.3M |
| 5 |
FedEx
FDX
|
+$91.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$97.2M |
| 2 |
Booking.com
BKNG
|
+$94.2M |
| 3 |
Phillips 66
PSX
|
+$82.9M |
| 4 |
Gilead Sciences
GILD
|
+$73.9M |
| 5 |
Snowflake
SNOW
|
+$51.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.09% |
| 2 | Financials | 15.5% |
| 3 | Healthcare | 14.12% |
| 4 | Consumer Discretionary | 11.36% |
| 5 | Industrials | 9.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RETA
451
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.64M | 0.02% |
95,726
-22,247
| -19% | -$766K |
|
|
CELL
452
DELISTED
PhenomeX Inc. Common Stock
CELL
| $3.61M | 0.02% |
1,347,074
-37,980
| -3% | -$100K |
|
453
Marcus & Millichap
MMI
$1.2B
| $3.53M | 0.02% |
102,426
-26,852
| -21% | -$953K |
|
454
Capri Holdings
CPRI
$1.81B
| $3.5M | 0.02% |
61,048
+7,921
| +15% | +$400K |
|
455
Harmonic Inc
HLIT
$1.15B
| $3.5M | 0.02% |
+267,020
| New | +$3.72M |
|
456
Perrigo
PRGO
$1.42B
| $3.49M | 0.02% |
102,336
-23,109
| -18% | -$814K |
|
457
Preferred Bank
PFBC
$1.25B
| $3.45M | 0.02% |
46,269
+3,282
| +8% | +$239K |
|
458
Affiliated Managers Group
AMG
$9.67B
| $3.44M | 0.02% |
21,717
-1,322
| -6% | -$187K |
|
459
Privia Health
PRVA
$3.05B
| $3.43M | 0.02% |
151,010
-29,078
| -16% | -$809K |
|
|
TBRG
460
DELISTED
TruBridge
TBRG
| $3.42M | 0.02% |
125,718
+375
| +0.3% | +$10.7K |
|
461
Mirum Pharmaceuticals
MIRM
$6.7B
| $3.41M | 0.02% |
175,122
-20,397
| -10% | -$403K |
|
462
Amneal Pharmaceuticals
AMRX
$6.04B
| $3.39M | 0.02% |
1,702,035
+259,725
| +18% | +$582K |
|
|
NGM
463
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $3.38M | 0.02% |
673,164
+604,515
| +881% | +$3.79M |
|
464
Dyne Therapeutics
DYN
$4.13B
| $3.36M | 0.02% |
289,993
+68,945
| +31% | +$798K |
|
465
Enphase Energy
ENPH
$4.85B
| $3.36M | 0.02% |
12,673
+8,287
| +189% | +$2.41M |
|
466
Astec Industries
ASTE
$1.19B
| $3.35M | 0.02% |
82,370
+3,681
| +5% | +$149K |
|
467
Mercado Libre
MELI
$94.6B
| $3.33M | 0.02% |
3,930
+1,388
| +55% | +$1.24M |
|
468
First Commonwealth Financial
FCF
$2.25B
| $3.32M | 0.02% |
237,565
-77,585
| -25% | -$1.09M |
|
469
HF Sinclair
DINO
$16.3B
| $3.24M | 0.02% |
62,517
+4,007
| +7% | +$231K |
|
470
Heritage Financial
HFWA
$1.21B
| $3.22M | 0.02% |
104,983
+19,930
| +23% | +$624K |
|
471
Gen Digital
GEN
$16.6B
| $3.21M | 0.02% |
149,697
-225,280
| -60% | -$4.98M |
|
472
Atara Biotherapeutics
ATRA
$71.2M
| $3.16M | 0.02% |
38,531
+24,318
| +171% | +$2.53M |
|
473
Herc Holdings
HRI
$4.82B
| $3.13M | 0.02% |
23,815
-2,926
| -11% | -$359K |
|
474
Protagonist Therapeutics
PTGX
$8.57B
| $3.1M | 0.02% |
284,115
+29,775
| +12% | +$251K |
|
475
Comfort Systems
FIX
$54B
| $3.05M | 0.02% |
+26,534
| New | +$3.09M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2022 Portfolio in Review
As of Q4 2022, Jacobs Levy Equity Management held 1,089 positions worth $14.8B, up 17% from $12.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $1.52B of net new capital in Q4 2022, opening 119 new positions and adding to 321 existing holdings. Its largest new stake was Fidelity National Information Services: 1,326,663 shares worth $90M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Booking.com, an estimated $94.2M trimmed.
- Jacobs Levy Equity Management's largest Q4 2022 buy was Fidelity National Information Services: 1,326,663 shares worth $90M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q4 2022, an estimated $132M increase.
- Jacobs Levy Equity Management's biggest Q4 2022 reduction was Booking.com, cutting an estimated $94.2M.
- Jacobs Levy Equity Management fully exited Cigna in Q4 2022, selling an estimated $97.2M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q4 2022.
- Jacobs Levy Equity Management opened 119 new positions and closed 155 in Q4 2022.
- Jacobs Levy Equity Management's portfolio value rose 17% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.